Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : SEVU: New Invention of Great Potential... -- Ignore unavailable to you. Want to Upgrade?

To: LaShark who wrote (1489)	2/7/2001 10:41:02 PM
From: Anthony@Pacific	Respond to of 1992

... :-) ....

To: LaShark who wrote (1489)	2/9/2001 4:51:41 PM
From: StockDung	Read Replies (1) \| Respond to of 1992

BioPulse's Tijuana Cancer Clinic Raises Concerns in Mexico Tijuana, Mexico, Feb. 9 (Bloomberg) -- BioPulse International Inc.'s cancer clinic in Tijuana, which performs controversial treatments include placing patients in daily comas, is to be inspected by local authorities who say those therapies may be illegal. Mexican health officials from the northwestern state of Baja California, which borders California, say they will visit the clinic to verify that it isn't violating its license, which permits it only to perform ambulatory therapy. ``Although we haven't done a recent inspection, we've heard that they are conducting treatments that, to be benevolent, I would call novel,'' said Alfredo Gruel, head of regulation at the state's Public Health Service Institute. He said such treatments weren't mentioned in BioPulse's license request. Gruel said he is checking with Mexico's federal authorities to find out if treatments similar to those BioPulse performs had been permitted in Mexico City. ``We aren't against alternative medicine, but we should look after people's health,'' he said. Last year, the state's health authorities closed 12 clinics in Tijuana, he said. Jonathan Neville, BioPulse's chief executive, declined to comment on the Mexican health official's statements. Mexico's concerns about the clinic were earlier reported by the San Diego Union. Last month, Bloomberg News reported that publicly traded BioPulse's cancer therapies haven't been proven safe or effective, and may be dangerous, according to U.S. cancer experts. In midday trading, BioPulse shares were quoted at $7.47, down 9 cents. --David Evans in Los Angeles, (310) 910-8811 or davidevans@bloomberg.net and Eduardo Garcia in Mexico City through the New York newsroom (212) 318-2300/fk

To: LaShark who wrote (1489)	2/13/2001 2:21:47 PM
From: StockDung	Read Replies (2) \| Respond to of 1992

FTC conducting inquiry into BioPulse advertising WASHINGTON, Feb 13 (Reuters) - The Federal Trade Commission in conducting an inquiry into BioPulse International Inc.'s (OTC BB:BIOP.OB - news) advertising of health-care products and treatments, the biotechnology company said on Tuesday. The purpose of the probe ``is to determine whether we have engaged in unfair or deceptive acts or practices, including whether we can substantiate claims we have made relating to treatments for cancer and other diseases,'' BioPulse said in a filing with the Securities and Exchange Commission. The company said it received a letter from the FTC on Feb. 2 notifying it of the probe. BioPulse, which is seeking treatments for cancer and other diseases, quoted the FTC as saying the inquiry should not be viewed as an accusation of wrongdoing. BioPulse President Loran Swensen did not immediately return a telephone call seeking further comment. A company spokesman, John Liviakis, said, ``I didn't get the impression it (the FTC inquiry) was anything major.'' Shares of San Diego-based BioPulse were down 1/16 to $5-7/16 in afternoon trade on the Bulletin Board. The stock has a 52-week high of $12-1/8 and a low of $2. xxxxxxxxxxxxxxxxxxx